- 询价
- 2026年02月09日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- ATCC Number：
HB-10494™
- 库存：
大量
- 免疫类型：
IgG1
- 细胞形态：
淋巴样
- 物种来源：
小鼠
- 是否是肿瘤细胞：
0
- 运输方式：
冻存运输
- 生长状态：
悬浮生长
| Designations: | 7E11C5 [7E11-C5] | ||
| Depositors: | Cytogen Corporation | ||
| Isotype: | IgG1 | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | suspension | ||
| Organism: | Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma) | ||
| Morphology: | lymphoblast |
||
| Source: | Cell Type: hybridoma: B lymphocyte; | ||
| Cellular Products: | immunoglobulin; monoclonal antibody; against human prostate cancer antigen | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Tumorigenic: | Yes | ||
| Comments: | Animals were immunized with live LNCaP cells and purified plasma membranes from LNCaP cells. Spleen cells were fused with P3X63Ag8.653 myeloma cells. The antibody reacts selectively with cells from both normal and neoplastic prostatic epithelium. By immunofluorescence staining, the reaction was much stronger with neoplastic than normal epithelium. The antigen recognized by 7E11C5 appears to be present in sera from patients with prostate cancer. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. Medium Renewal: Every 2 to 3 days |
||
| Preservation: | Freeze medium: Complete growth medium, 90%; DMSO, 10% Storage temperature: liquid nitrogen vapor temperature |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
||
| References: | 21308: Horoszewicz JS. Hybridoma and monoclonal antibody 9H10-A4 specific to an antigen of LNCaP cells. US Patent 5,578,484 dated Nov 26 1996 22007: Horoszewicz JS. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. US Patent 5,162,504 dated Nov 10 1992 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验补体成分 C5(C5a/C5b) 补体成分：C5 血清浓度(μg/ml)：70 分子量(kDa)：190 亚单位(链)及分子量(kDa)：α∶115；β∶75 激活产物：C5a；C5b 生物学活性：C5a 强的过敏毒素作用、趋化作用、促代谢作用及免疫调节作用 C5b
网络 五、C5分子 C5是形成膜攻击复合体（MAC）的第1个补体分子。C5由以二硫键相连接的α、β链组成，分子量190 kDa，其中α链为115kDa，β链为75kDa（图5-9）。C5与C3和C4的结构相类似，但没有链内硫酯键。靠近N端的第74-75位精氨酸一亮氨酸键为C5转化酶作用的部位。在C5转化酶的作用下，C5α链
人补体C5 (C5)ELISA 试剂盒 ( 用于血清、血浆、细胞培养上清液和其它生物体液内 ) 原理 本实验采用双抗体夹心 ABC-ELISA 法。用抗人 C5 单抗包被于酶标板上，标准品和样品中的 C5与单抗结合，加入生物素化的抗人 C5 ，形成免疫复合物连接在板上，辣根过氧化物酶标记的 Streptavidin 与生物素结合，加入底物工作液显蓝色，最后加终止液硫酸，在 450nm 处测
技术资料暂无技术资料 索取技术资料
